PARPi and Ovarian Cancer Survival

Launched by SHANGHAI GYNECOLOGIC ONCOLOGY GROUP · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "PARPi and Ovarian Cancer Survival," is studying how well certain medications called PARP inhibitors (PARPi) help patients with advanced or recurrent ovarian cancer. These drugs are used as maintenance therapy, which means they help keep cancer from coming back after initial treatment. The trial aims to gather real-world information about how these medications impact survival rates among women diagnosed with advanced stages of ovarian cancer. Researchers will look at factors like the type of PARPi used, the patients' genetic information, and whether other treatments were given alongside PARPi.

To be eligible for this trial, women must be either newly diagnosed with advanced ovarian cancer or have had a first recurrence of the disease after initial treatment. Specifically, they should have been diagnosed with certain types of ovarian or related cancers between December 2013 and December 2024. Participants will need to have complete information on their treatments and follow-up care. While the trial has not started recruiting participants yet, it is important for those who meet the criteria to understand that they will be contributing to valuable research that could improve future treatments for ovarian cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• Group 1:
• • Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December 2024.
• • Complete data on first-line treatment and maintenance therapy.
• • Availability of follow-up data.
• Group 2:
• • Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December 2024.
• • Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
• • Complete data on second-line treatment and maintenance therapy.
• • Availability of follow-up data.
• Exclusion Criteria:
• Group 1:
• • Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
• • Missing first-line or follow-up data.
• Group 2:
• • Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
• • Patients with second relapse.
• • Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.
• • Missing second-line or follow-up data.